NASDAQ · GOVX
GeoVax Labs, Inc.
Healthcare · Biotechnology
$0.35▲ 1.82% ($0.01)at close
After hours$0.36▲ 2.16%7:51 PM ET
Market cap
$2.59M
P/E
-0.03
EPS (TTM)
-$4.47
Next earnings
Nov 12, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
1 more note
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Price vs. estimate range
Assumption scenarios, not confidence intervals
Bull $1.74; price used $0.35
Bull $1.74; price used $0.35
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 0.0%
- Discount rate
- 17.7%
USD · FY 2025 · Price used $0.35 · Price Sep 29, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 97.8% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow grew 32.95% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies.
Market multiples
Stock splits
Every 25 shares became 1
Every 15 shares became 1
Every 20 shares became 1
Every 2000 shares became 1
Every 500 shares became 1
Every 50 shares became 1
Profitability & growth
Analyst consensus
6
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 12, 2026
Q3 FY26 · EPS est -$1.09 · Revenue est —
View
Institutional Sentiment
GeoVax Labs, Inc. · GOVX
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.